PTC Therapeutics (PTCT) PT Raised to $60 at TD Cowen Following FDA Acceptance and Priority Review for Vatiquinone NDA
Tweet Send to a Friend
TD Cowen analyst Joseph Thome raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $60.00 (from $50.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
